Oscar Health reported a jump in its costs to serve customers, bringing down its profitability.

AI-generated source summary

The analysis discusses Oscar Health's performance, noting a 22% increase year-to-date and a recent earnings release. While revenue increased to $2.863 billion in the three months ending June 30, 2025, medical costs also jumped significantly to $2.552 billion. Membership grew by 33%, reaching just over 2 million. Management anticipates market stabilization and profitability by 2026. The discounted cash flow valuation model indicates an intrinsic value of $36.37 per share, down from a previous $40. Despite increased costs and decreased profitability, the analyst maintains a buy rating due to the expectation of normalized costs next year. The target is $36.37.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   20 Aug 2025, 23:16 UTC

   The analyst published the original source item.

2. First prediction resolved

   13 Nov 2025, 18:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   13 Nov 2025, 18:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:13 UTC

   Tahlil Plus began monitoring the extracted predictions.